Gene info: ID 2157

Gene: F8

GENE ID: 2157

Description: coagulation factor VIII

Gene type: protein-coding

Location: Xq28

dbXrefs: Ensembl:ENSG00000185010 MIM:300841 Vega:OTTHUMG00000022688 UniprotKB:P00451

RefSeq: NG_011403.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : NA (AD) NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
DPP8	0.9
ATAD1	0.879
FBXL17	0.878
DCLRE1A	0.878
TMED8	0.876
OPA1	0.876
RAB11FIP2	0.876
KRAS	0.874
DLD	0.874
STAU2	0.873

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.504
OR4F29	-0.455
SGMS2	-0.401
TGFB3	-0.4
ANXA13	-0.388
SH2D1A	-0.386
HEY2	-0.382
CSAG1	-0.381
C7orf61	-0.376
RAI14	-0.376

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00055	Drotrecogin alfa	BiotechDrug	98530-76-8	Approved\|Investigational\|Withdrawn	Target
DB00100	Coagulation Factor IX (Recombinant)	BiotechDrug	181054-95-5	Approved\|Investigational	Target
DB12872	Vonicog Alfa	BiotechDrug	109319-16-6	Approved\|Investigational	Target
DB13133	Von Willebrand Factor Human	BiotechDrug	109319-16-6	Approved\|Investigational	Target
DB13151	Anti-inhibitor coagulant complex	BiotechDrug		Approved\|Investigational	Target
DB13152	Coagulation Factor IX Human	BiotechDrug	9001-28-9	Approved	Target
DB13933	Nonacog beta pegol	BiotechDrug	1175512-71-6	Approved\|Investigational	Target
DB13151	Anti-inhibitor coagulant complex	BiotechDrug		Approved\|Investigational	Enzyme
DB09130	Copper	Small Molecule	7440-50-8	Approved\|Investigational	Carrier

ID	Drug Name	Action	PubMed
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of F8 mRNA"	28903501
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of F8 mRNA"	19114083
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of F8 mRNA"	21346803
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of F8 mRNA"	21346803
C017906	3-dinitrobenzene	3-dinitrobenzene results in decreased expression of F8 mRNA	21983209
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in increased expression of F8 mRNA"	18648102
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F8 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F8 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased activity of F8 protein	12730105
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of F8 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of F8 mRNA	19770486
D000535	Aluminum	Aluminum affects the folding of F8 protein	15349964
D000535	Aluminum	[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein	15349964
D044966	Anti-Retroviral Agents	Anti-Retroviral Agents results in decreased expression of F8 protein	19929230
C006632	arsenic trioxide	[Tretinoin co-treated with arsenic trioxide] results in decreased expression of F8 protein	15894607
D017636	Asbestos, Amphibole	"Asbestos, Amphibole results in increased expression of F8 mRNA"	22352330
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased mutagenesis of F8 gene	25435355
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of F8 mRNA	22228805
D001622	Betaine	Betaine affects the localization of and results in increased secretion of F8 protein	22973456
D001622	Betaine	Betaine affects the localization of and results in increased secretion of F8 protein mutant form	22973456
D001622	Betaine	Betaine results in increased secretion of F8 protein	22973456
D001622	Betaine	Betaine results in increased secretion of F8 protein mutant form	22973456
C006780	bisphenol A	bisphenol A results in decreased expression of F8 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of F8 gene	28505145
C018475	butyraldehyde	butyraldehyde results in increased expression of F8 mRNA	26079696
D002104	Cadmium	Cadmium results in decreased expression of F8 mRNA	24376830
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of F8 promoter	22457795
D002118	Calcium	Calcium results in increased activity of [F8 protein alternative form binds to F8 protein alternative form]	11513607
D002118	Calcium	[Copper co-treated with Calcium] results in increased activity of [F8 protein alternative form binds to F8 protein alternative form]	11513607
D003276	Contraceptives, Oral	"Contraceptives, Oral results in increased expression of F8 protein"	133615
D003300	Copper	[Copper co-treated with Calcium] results in increased activity of [F8 protein alternative form binds to F8 protein alternative form]	11513607
D003300	Copper	Copper promotes the reaction [F8 protein alternative form binds to F8 protein alternative form]	11513607
D016572	Cyclosporine	Cyclosporine results in decreased expression of F8 mRNA	20106945
D016572	Cyclosporine	Cyclosporine results in increased expression of F8 protein	2859508
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of F8 mRNA	23640034\|2391405
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of F8 mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of F8 mRNA	27392435
C035276	eicosapentaenoic acid ethyl ester	eicosapentaenoic acid ethyl ester results in decreased activity of F8 protein	14614217
D052244	Endocrine Disruptors	Endocrine Disruptors results in increased expression of F8 mRNA	25198161
D004997	Ethinyl Estradiol	[Ethinyl Estradiol co-treated with Gestodene] affects the activity of F8 protein	11720199
D004997	Ethinyl Estradiol	[Ethinyl Estradiol co-treated with Gestodene] results in increased expression of F8 protein	12618251
D004997	Ethinyl Estradiol	[Ethinyl Estradiol co-treated with Levonorgestrel] results in increased expression of F8 protein	12618251
D004997	Ethinyl Estradiol	[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of F8 protein	12618251
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of F8 mRNA	17555576\|1794274
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of F8 mRNA	17942748
C442659	ethinyl estradiol-desogestrel combination	ethinyl estradiol-desogestrel combination results in increased expression of F8 protein	12618251
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of F8 mRNA	23649840
C082360	fipronil	fipronil results in increased expression of F8 mRNA	23962444
D005472	Fluorouracil	F8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
D005557	Formaldehyde	Formaldehyde results in increased expression of F8 mRNA	23649840
D002955	Leucovorin	F8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
C039281	furan	furan results in increased methylation of F8 gene	22079235
D005839	Gentamicins	Gentamicins results in increased expression of F8 protein	16051741
C033273	Gestodene	[Ethinyl Estradiol co-treated with Gestodene] affects the activity of F8 protein	11720199
C033273	Gestodene	[Ethinyl Estradiol co-treated with Gestodene] results in increased expression of F8 protein	12618251
D017313	Fenretinide	Fenretinide results in decreased expression of F8 mRNA	28973697
C051890	irinotecan	F8 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of F8 mRNA	27392435
D008713	Methimazole	Methimazole results in increased expression of F8 mRNA	22504374
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of F8 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of F8 mRNA	23649840
D008775	Methylprednisolone	Methylprednisolone results in increased expression of F8 protein	20405515
C017576	norgestimate	[Ethinyl Estradiol co-treated with norgestimate] results in increased expression of F8 protein	12618251
D016912	Levonorgestrel	[Ethinyl Estradiol co-treated with Levonorgestrel] results in increased expression of F8 protein	12618251
D009966	Orphenadrine	Orphenadrine affects the expression of F8 mRNA	23665939
D010100	Oxygen	Oxygen deficiency results in increased expression of F8 mRNA	26516004
D052638	Particulate Matter	Particulate Matter results in increased expression of F8 protein	21029357
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of F8 mRNA	28973697
C101816	perfluoro-n-nonanoic acid	perfluoro-n-nonanoic acid results in decreased expression of F8 mRNA	21984479
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of F8 mRNA alternative form	18501439
D010634	Phenobarbital	NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of F8 mRNA]	19482888
D010634	Phenobarbital	Phenobarbital results in decreased expression of F8 mRNA	19482888
D011441	Propylthiouracil	Propylthiouracil results in increased expression of F8 mRNA	22504374
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased activity of F8 protein	16359964
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of F8 protein	15850603
C059514	resveratrol	resveratrol results in increased expression of F8 protein	16775512
D013629	Tamoxifen	Tamoxifen results in increased expression of F8 protein	15850603
D013629	Tamoxifen	Tamoxifen affects the expression of F8 mRNA	17555576
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of F8 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of F8 mRNA	25975270
D014212	Tretinoin	[Tretinoin co-treated with arsenic trioxide] results in decreased expression of F8 protein	15894607
C012589	trichostatin A	trichostatin A results in decreased expression of F8 mRNA	24935251
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of F8 mRNA	19042947
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F8 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of F8 mRNA	24935251\|2800136
D014635	Valproic Acid	Valproic Acid results in decreased methylation of F8 gene	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in increased expression of F8 protein	21029357
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of F8 gene	25560391
C025643	vinclozolin	vinclozolin results in increased expression of F8 mRNA	20566332
D014874	Water Pollutants, Chemical	"Water Pollutants, Chemical results in increased expression of F8 mRNA"	25198161

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005507	copper ion binding	-	IEA	-
GO:0005515	protein binding	-	IPI	7756647
GO:0016491	oxidoreductase activity	-	IEA	-
GO:0070492	oligosaccharide binding	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0002576	platelet degranulation	-	TAS	-
GO:0006888	ER to Golgi vesicle-mediated transport	-	TAS	-
GO:0006953	acute-phase response	-	IEA	-
GO:0007596	blood coagulation	-	TAS	8275087
GO:0007597	blood coagulation, intrinsic pathway	-	IBA	21873635
GO:0007597	blood coagulation, intrinsic pathway	-	TAS	-
GO:0030168	platelet activation	-	IEA	-
GO:0048208	COPII vesicle coating	-	TAS	-
GO:0055114	oxidation-reduction process	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000139	Golgi membrane	-	IEA	-
GO:0005576	extracellular region	-	NAS	14718574
GO:0005576	extracellular region	-	TAS	-
GO:0005615	extracellular space	-	IBA	21873635
GO:0005615	extracellular space	-	IEA	-
GO:0005788	endoplasmic reticulum lumen	-	TAS	-
GO:0005886	plasma membrane	-	TAS	-
GO:0030134	COPII-coated ER to Golgi transport vesicle	-	TAS	-
GO:0031093	platelet alpha granule lumen	-	TAS	-
GO:0033116	endoplasmic reticulum-Golgi intermediate compartment membrane	-	TAS	-

KEGG ID	KEGG Term
hsa04610	Complement and coagulation cascades

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-114608	Platelet degranulation	TAS
R-HSA-140837	Intrinsic Pathway of Fibrin Clot Formation	TAS
R-HSA-140875	Common Pathway of Fibrin Clot Formation	TAS
R-HSA-140877	Formation of Fibrin Clot (Clotting Cascade)	TAS
R-HSA-199977	ER to Golgi Anterograde Transport	TAS
R-HSA-199991	Membrane Trafficking	TAS
R-HSA-204005	COPII-mediated vesicle transport	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-446203	Asparagine N-linked glycosylation	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-5694530	Cargo concentration in the ER	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76005	Response to elevated platelet cytosolic Ca2+	TAS
R-HSA-948021	Transport to the Golgi and subsequent modification	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
7748355	Reduced P300 amplitude in relation to family history of alcoholism and antisocial personality disorder among young men at risk for alcoholism. (1993)	Hesselbrock V	Alcohol Alcohol Suppl
24850280	Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. (2014 Jul 1)	Brody AL	JAMA Psychiatry